Eplontersen PKPD model
Indication: Hereditary transthyretin-mediated amyloidosis (hATTR)
Population PK/PD simulator for eplontersen (WAINUA), a GalNAc3-conjugated ASO for transthyretin amyloidosis. Two-compartment PK with indirect response PD model. Based on Diep et al. 2022.
Drug Overview
Clinical Context
- Molecular Target
- TTR mRNA
- Drug Class
- Antisense Oligonucleotide (ASO)
- Therapeutic Area
- Transthyretin Amyloidosis (ATTR)
- Indication
- Hereditary transthyretin-mediated amyloidosis (hATTR)
- Route of Administration
- SC
Model Information
- Model Type
- 2-CMT PK + Indirect Response PD
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Eplontersen allows you to explore concentration-time profiles under different dosing scenarios. The underlying 2-CMT PK + Indirect Response PD model characterizes the pharmacokinetics of this antisense oligonucleotide (aso) following sc administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Eplontersen PK simulator?
This is a free, interactive pharmacokinetic simulator for Eplontersen used in Hereditary transthyretin-mediated amyloidosis (hATTR). It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Eplontersen belong to?
Eplontersen is classified as a Antisense Oligonucleotide (ASO) that targets TTR mRNA. It is used in the Transthyretin Amyloidosis (ATTR) therapeutic area.
What route of administration does this model simulate?
This simulator models SC administration of Eplontersen. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a 2-CMT PK + Indirect Response PD model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the Eplontersen simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community